As of November this year, based on Abbott Laboratories's most recent financial report, the company's trailing twelve months EPS is $2.69. Abbott Laboratories's earnings per share in 2025 was reported at $3.73, marking a decline from $7.67 in 2024. Abbott Laboratories's EPS for the quarterly period ending on Sep 30, 2026 came in at $0.53.
The yearly earnings per share during 2025 was $3.73, a decline of 51.4% compared to $7.67 recorded in 2024. The quarterly earnings per share for the period ending Sep 30, 2026, was $0.53, showing a 43.6% decline compared to the same quarter last year. The trailing twelve months EPS for ABT is $2.69 as of September 2026. Abbott Laboratories's full-year EPS for 2024 was $7.67, a 133.8% rise compared to the previous year.
In the past 12 months, Abbott Laboratories has recorded an earnings per share growth rate of -43.6% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of -1.8% per year. In the last five years, the company had an average annual EPS growth of 8.2%. When assessed over a ten-year period, ABT's average EPS annual growth was 2.4%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | 13.85 | 178.7% | 5.3% | N/A |
| BSX Boston Scientific Corp | 18.59 | 55.6% | 63.3% | N/A |
| MDT Medtronic Plc | 24.78 | 3.3% | 9.8% | 6.9% |
| AZN Astrazeneca plc | 25.96 | 45.4% | 46% | 22% |
| NVS Novartis AG | 30.51 | 21.8% | 31.2% | 15.2% |
| TMO Thermo Fisher Scientific Inc | 37.04 | 7.2% | 0% | 2% |
| ABT Abbott Laboratories | 39.79 | -51.4% | -1.8% | 8.2% |
| PFE Pfizer Inc | 40.86 | -3.5% | -37.4% | -3.7% |
| JNJ Johnson & Johnson | 42.62 | 90.6% | 17.7% | 14.8% |
All data is based on quarterly TTM periods, unless otherwise specified.